树突状细胞联合细胞因子诱导的杀伤细胞免疫治疗对肾癌和非小细胞肺癌患者免疫功能的影响  

Effect of dendritic cells combined with CIK immunotherapy on immunity function of patients with renal cancer or nonsmall cell lung cancer

作　　者：郑培浩[1] 刘毅[1] 岑坚[1] 李莉[1] 赵德峰[1] 沈建良[1] 

机构地区：[1]解放军海军总医院血液科,北京100048

出　　处：《临床军医杂志》2014年第2期124-127,共4页Clinical Journal of Medical Officers

摘　　要：目的探讨自体树突状细胞（DCs）联合细胞因子诱导的杀伤细胞（CIK）过继免疫治疗对肾癌和非小细胞肺癌患者免疫功能的影响。方法选取Ⅲ～Ⅳ期肾癌患者28例和Ⅲ-Ⅳ期非小细胞肺癌患者15例，分别于DCs—CIK细胞免疫治疗前和治疗后第30天监测患者免疫功能指标，包括外周血T淋巴细胞亚群以及干扰素-γ（IFN-γ）、肿瘤坏死因子（TNF-α）、白细胞介素-10（IL-10）、IL-6、IL-4、IL-2等细胞因子水平。结果肾癌患者经DCs—CIK治疗后30d与治疗前比较，外周血IFN-γ、IL-2升高（P〈0．05），IL-10降低（P〈0．05），TNF—α、IL-6、IL-4则无明显变化（P〉0．05）。T淋巴细胞亚群中CD3＋T细胞、CD3＋CD8＋T细胞、NKT细胞比例较治疗前有所提高（P〈0．05），而CD3＋CD4＋T细胞、NK细胞、调节性T细胞（Tregs）则无明显变化（P〉0．05）。非小细胞肺癌患者DCs—CIK治疗后30d与治疗前比较，外周血IFN-γ、IL-2升高（P〈0．05），TNF-α、IL-10、IL-6、IL4则无明显变化（P〉0．05）。T淋巴细胞亚群中CD3＋T细胞、CD3＋CD8＋T细胞、NKT细胞比例较治疗前有所提高，CD3＋CD4＋T细胞、NK细胞、Treg细胞则无明显变化。结论DCs—CIK细胞免疫治疗能改善晚期肾癌和非小细胞肺癌患者的免疫功能。Objective To investigate the effects of dendritic cells （DCs） combined with cytokine induced killer （CIK） immuno-therapy on the immune function of patients with renal cancer or non-small cell lung cancer. Methods A total of 28 patients with renal cancers and 15 patients with non-small cell lung cancers in stage m - IVof TNM were treated with DCs-CIK immunotherapy. We detected the immunity of the patients including CD3 ＋ , CD4 ＋ and CD8 ＋ T lymphoeytes, NK cells, NKT cells, Treg cells, eytokins （IFN-γ, TNF-oL, IL-10, IL-6, IL-4 and IL-2） in the peripheral blood of the patients before and on the 30th day after the beginning of the immunotherapy. Results On the 30th day after DCs-CIK immunotherapy, the levels of IFN-7 and IL-2 and the ratios of CD3 ＋ T lymphoeytes, CD3 ＋ CD8 ＋ T lymphocytes and NKT cells in the peripheral blood of the patients with renal cancers were more higher than that before （ P 〈 0.05 ）. The level of IL-10 was lower after immunotherapy than before （ P 〈 0.05 ）. There were no obvious changes in the levels of TNF-α, IL-6, IL-4 and in the ratios of CD3 ＋ CIM ＋ T lymphocytes, NK and Treg cells （P 〉 0.05）. On the 30th day after the beginning of immunotherapy, the levels of IFN-γ and IL-2 and the ratios of CD3 ＋ T lymphocytes, CD3 ＋ CD8 ＋ T lymphocytes and NKT cells in the peripheral blood of the patients with non-small cell lung cancers were more higher than that before immunotherapy （P 〈 0.05）. There were no obvious changes in the levels of TNF-α, IL-10, IL-6 and IL-4 and in the ratios of CD3 ＋ CD4 ＋ T lymphoeytes, NK cells and Treg cells. Conclusion DCs-CIK immunotherapy can improve the immune function of the patients with advanced renal cancer and non-small cell lung cancer.

关 键 词：树突状细胞 杀伤细胞 肾肿瘤 非小细胞肺癌 过继免疫细胞治疗 

分 类 号：R730.51[医药卫生—肿瘤]